SCHEMBL8367161

SCHEMBL8367161

CCc1ccnc2cc(Cl)ccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 2/20 0.58
SOS2 Q07890 1/20 0.58
CYP1A2 P05177 1/20 0.56
CCR1 P32246 1/20 0.53
ALDH1A1 P00352 1/20 0.52
KDM4E B2RXH2 2/20 0.51
PRNP P04156 2/20 0.51
RXFP1 Q9HBX9 2/20 0.51
LMNA P02545 2/20 0.51
HTT P42858 1/20 0.51
HSD17B10 Q99714 1/20 0.51
POLB P06746 2/20 0.50
KMT2A Q03164 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
FERMT2 Q96AC1 1/20 0.50
THRB P10828 1/20 0.49
NSD2 O96028 1/20 0.49
CHKA P35790 1/20 0.49
MAPT P10636 1/20 0.49
TDP1 Q9NUW8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11893054 0.87 NR4A2 (0.56) NR4A2SOS2CYP1A2CCR1ALDH1A1
SCHEMBL14394991 0.83 CCR1 (0.55) NR4A2SOS2CYP1A2CCR1KDM4E
SCHEMBL8066565 0.81 NR4A2 (0.58) NR4A2SOS2CYP1A2CCR1ALDH1A1
SCHEMBL10316082 0.79 HTR1A (0.57) CCR1ALDH1A1KDM4EKMT2A
SCHEMBL10316081 0.78 GAK (0.43) NR4A2SOS2CYP1A2ALDH1A1KDM4E
SCHEMBL10377143 0.77 POLB (0.63) NR4A2SOS2CYP1A2CCR1ALDH1A1
SCHEMBL8936216 0.77 POLB (0.44) NR4A2SOS2CYP1A2CCR1ALDH1A1
SCHEMBL2710661 0.77 NR4A2 (0.61) NR4A2SOS2CYP1A2CCR1ALDH1A1
SCHEMBL29491409 0.77 NR4A2 (0.61) NR4A2SOS2CYP1A2CCR1ALDH1A1
SCHEMBL29396540 0.76 NR4A2 (0.66) NR4A2SOS2CYP1A2CCR1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180214457-A1 USE OF CYMANQUINE COMPOUNDS AS ANTIMALARIAL AGENTS UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE 2018-08-02 US disclosed
US-20180022771-A1 CYMANQUINE COMPOUNDS AND DERIVATIVES THEREOF AND USES THEREOF UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE 2018-01-25 US disclosed
US-8278327-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2012-10-02 US disclosed
US-8163693-B2 Urea-containing peptides as inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2012-04-24 US disclosed
US-20110070168-A1 MACROCYCLIC PEPTIDES AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. (US) 2011-03-24 US disclosed
US-7906619-B2 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2011-03-15 US disclosed
US-20110021509-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2011-01-27 US disclosed
US-20100331348-A1 TROPANE DERIVATIVES USEFUL AS PESTICIDES SYNGENTA CROP PROTECTION, INC. (US) 2010-12-30 US disclosed
US-7786139-B2 PDE10 inhibitors and related compositions and methods OMEROS CORPORATION (US) 2010-08-31 US disclosed
WO-2010081851-A1 PIPERIDIN-4-YLPIPERAZINE COMPOUNDS FOR THE TREATMENT OF HCV INFECTION GENOSCIENCE PHARMA (FR) 2010-07-22 WO disclosed
US-7745444-B2 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-06-29 US disclosed
CN-101712688-A Hybrid QA molecules wherein Q is an aminoquinoline and A is an antibiotic residue, their synthesis and their uses as antibacterial agent PALUMED SA 2010-05-26 CN disclosed
US-20100124545-A1 CYCLIC CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF AS OF HEPATITIS C VIRUS ACHILLION PHARMACEUTICALS, INC. (US) 2010-05-20 US disclosed
US-20090082261-A1 UREA-CONTAINING PEPTIDES AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. (US) 2009-03-26 US disclosed
US-20090048297-A1 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS (US) 2009-02-19 US disclosed
US-20080311079-A1 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-12-18 US disclosed
US-20080300240-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS OMEROS CORPORATION (US) 2008-12-04 US disclosed
US-7417152-B2 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin B1 receptor antagonists for the treatment of inflammatory diseases ELAN PHARMACEUTICALS, INC. (US) 2008-08-26 US disclosed
CN-101068821-A Hybrid QA molecules where Q is an aminoquinoline and A is an antibiotic residue, their synthesis and use as antibacterial agents PALUMED SA (FR) 2007-11-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300240-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS PDE10A, PDE9A, PDE7A NR4A2 1752/4885SOS2 4420/4885CYP1A2 1182/4885
US-20110070168-A1 MACROCYCLIC PEPTIDES AS INHIBITORS OF VIRAL REPLICATION VIP, ZC3HAV1, ZC3HAV1L NR4A2 2371/4885SOS2 4651/4885CYP1A2 4526/4885
US-20180022771-A1 CYMANQUINE COMPOUNDS AND DERIVATIVES THEREOF AND USES THEREOF MCL1, NRAS, NCL NR4A2 2944/4885SOS2 2839/4885CYP1A2 3126/4885
US-20090082261-A1 UREA-CONTAINING PEPTIDES AS INHIBITORS OF VIRAL REPLICATION VIP, SLC14A1, RPL35 NR4A2 4130/4885SOS2 4584/4885CYP1A2 4772/4885
US-20090048297-A1 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION VIP, ZC3HAV1, CCL5 NR4A2 2376/4885SOS2 4681/4885CYP1A2 4528/4885
US-20080311079-A1 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease SERPINB1, PRSS1, SPINT2 NR4A2 3687/4885SOS2 1274/4885CYP1A2 851/4885
US-20100124545-A1 CYCLIC CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF AS OF HEPATITIS C VIRUS CPS1, CCKAR, C1R NR4A2 1447/4885SOS2 4635/4885CYP1A2 1423/4885
US-20100331348-A1 TROPANE DERIVATIVES USEFUL AS PESTICIDES DDT, ACHE, TPM3 NR4A2 1863/4885SOS2 3939/4885CYP1A2 20/4885
US-20180214457-A1 USE OF CYMANQUINE COMPOUNDS AS ANTIMALARIAL AGENTS RECQL, ARG2, POLRMT NR4A2 2726/4885SOS2 3852/4885CYP1A2 854/4885
US-20110021509-A1 PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS PDE10A, PDE9A, PDE7A NR4A2 1677/4885SOS2 4426/4885CYP1A2 1256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.